Company
Headquarters: Heping, China
CN¥8.10 Billion
CNY as of July 1, 2025
US$1.13 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Roche | $260.54 B |
| Novartis | $243.50 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Boai NKY Medical Holdings Ltd. develops, manufactures, and sells polyvinylpyrrolidone (PVP) series products worldwide. The company offers KoVidone and PolyKoVidone line of products representing Povidone, Crospovidone, and Copovidone pharmaceutical excipients; OraRez line of PVM/MA copolymer and derivatives representing functional polymers for bioadhesive/mucoadhesive applications; KoVidone-1 broad spectrum biocidal, antifungal, and antiviral agents; and pharmaceutical solvents and intermediates. It also offers polymers, vinyl and vinyl ether compounds, PolyViscol, KoVidone I, WhiVidone, and PVPP. Its products are used in pharma, industrial, oral care, cosmetics, food and beverage, and other sectors. The company was formerly known as Boai NKY Pharmaceuticals Ltd. and changed its name to NKY medical holding Ltd. in March 2016. Boai NKY Medical Holdings Ltd. was founded in 1987 and is based in Heping, China.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥1.54 B |
| EBITDA | CN¥432.4 M |
| Gross Profit TTM | CN¥682.1 M |
| Profit Margin | 20.09% |
| Operating Margin | 22.85% |
| Quarterly Revenue Growth | -17.70% |
Boai NKY Medical Holdings Ltd has the following listings and related stock indices.
Stock: SZSE: 300109 wb_incandescent